TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07038343: A Phase 1/2, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced

Sponsor: Avenzo Therapeutics, Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 480 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,013,850

Rescue Site Savings

+$6,597,360

Unlock Full NCT07038343 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07038343 Rescue Dossier →